Summary
The Walker 256 carcinosarcoma growing in the rat was irradiated with a surface dose of 240 rad on each of three consecutive days and treated for six days with 30 mg/kg of the carcinostatic drug ICRF 159. The combined treatment led to a greater inhibition of tumour growth than with X-radiation alone (p<0.01). ICRP 159 may thus be able to sensitize the tumour tissue to irradiation, particulary since an increase of the tissue pO2 has been observed after ICRF 159 treatment, but an additive effect of the two therapies can not be excluded.
Zusammenfassung
Walker-256-Carcinosarkome der Ratte wurden an drei aufeinanderfolgenden Tagen jeweils mit 240 rad bestrahlt. Die Tumor-tragenden Ratten erhielten vor und während der Strahlenbehandlung täglich 30 mg/kg des Dioxopiperazins ICRF 159. Die Kombination von Strahlen und Chemotherapie führte zu einer stärkeren Hemmung des Tumorwachstums als die Strahlentherapie allein (p<0.01). Eine strahlensensibilisierende Wirkung des ICRF 159 ist denkbar, nachdem die Substanz am gleichen Tumor zu einer Erhöhung des Gewebe-pO2 geführt hat. Ein rein additiver Effekt bei der Kombinationstherapie läßt sich andererseits nicht ausschließen.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Baumgärtl,H., Lübbers,D.W., Norpoth,K., Seidel,E. Ziegler,H.: In preparation
Documenta Geigy: Wissenschaftliche Tabellen, 1967
Duke,D.I., Field,E.O., Finch,M., Hellmann,K., Tucker,A.S.B., Tucker,D.F.: Immunosuppression by the bis dioxopiperazines ICRP 154 and ICRF 159
Field,E.O., Hellmann,K., Dawson,K.B., Sharpe,H.B.A.: ICRF 159: A new mitosis blocking agent. Report: Third meeting of the European study group for cell-proliferation. Varna. Bulgaria, April 20–24, 1970
Hellmann,K.: Serendipity in cancer chemotherapy. New Scientist and Science J. 111–113, (1971/1)
Hellmann,K.: Anticancer drugs. Chem. Britain 8, 69–72 (1972a)
Hellmann,K.: Effect of ICRF 159 on immune responses. Proc. roy. Soc. Med. 65, 264–265 (1972b)
Hellmann,K.: Current clinical and experimental studies with ICRF 159. In: Stacher, A. (Ed.): Leukämie und maligne Lymphome, pp. 425–427. München: Urban und Schwarzenberg 425–427 (1972)
Hellmann,K.: Preliminary clinical assessment of ICRF 159 (NSC-129943) in Bronchogeniccarcinoma. Cancer Chemother. Rep. 4, 243 (1973)
Hellmann,K., Burrage,K.: Control of malignant metastases by ICRF 159. Nature (Lond.) 224, 274–275 (1969)
Hellmann,K., Newton,K.A., Whitmore,D.N., Hanham,I.W.F., Bond,J.V.: Preliminary clinical assessment of ICRF 159 in acute leukaemia and lymphosarcoma. Brit. med. J. 1969I, 822–824 (1969)
Hellmann,K., Field,E.O.: Effect of ICRF 159 on the mammalian cell-cycle. Significance for use in cancer chemotherapy. J. nat. Canc. Inst. 44, 539–543 (1970)
James,S.E., Salsbury,A.J.: Effect of (±)-1,2-Bis-(3,5-dioxopiperazine-1-yl) propane on Tumour blood vessels and its relationship to the antimetastatic effect in the Lewis lung carcinoma. Cancer. Res. 34, 839–842 (1974)
Le Serve,A.W., Hellmann,K.: Metastases and the normalisation of tumour blood vessels by ICRF 159: A new type of drug action. Brit. med. J. 1972II, 597–601
Salsbury,A.J., Burrage,K., Hellmann,K.: Inhibition of metastatic spread by ICRF 159: Selective deletion of a malignant characteristic. Brit. med. J. 1970IV, 344–346
Tucker,D.F., Finch,M.D.: Immunosuppression by the bis dioxopiperazines: Effects on antibody-forming cell and serum titres. J. Nat. Cancer Inst. 48, 1347–1354 (1972)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Norpoth, K., Schaphaus, A., Ziegler, H. et al. Combined treatment of the Walker tumour with radiotherapy and ICRF 159. Z. Krebsforsch. 82, 329–334 (1974). https://doi.org/10.1007/BF00285567
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00285567